A multicenter, open-label, follow-up trial evaluating the long-term safety of levetiracetam individualized dose from 1000 to 3000 mg/day (oral tablets of 500 mg b.i.d.), used as monotherapy in subjects (at least 16 years) suffering from epilepsy and coming from the N01061 or the N01093 trials.
Phase of Trial: Phase III
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Levetiracetam (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors UCB Pharma Inc
- 06 Jul 2007 Status changed from in progress to completed.
- 14 Nov 2005 New trial record.